StockData
Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc. (NTLA) stock

NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.78−0.08 (-0.81%)

Close on Nov 17, 2026Market cap $1.37BP/E –Yield –

Intellia Therapeutics cash

Cash and short-term investments held at the end of each period.

Intellia Therapeutics's cash was $437.76M at Jun 30, 2026. For fiscal 2025 it was $449.88M, down 25.2% from the year before. Over ten years it grew 19.5% a year on average. The highest annual figure on record is $1.19B in fiscal 2022.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$449.88M-25.2%
FY2024Dec 31, 2024$601.52M-34.1%
FY2023Dec 31, 2023$912.22M-23.5%
FY2022Dec 31, 2022$1.19B+59.3%
FY2021Dec 31, 2021$748.69M+25.3%
FY2020Dec 31, 2020$597.37M+113.6%
FY2019Dec 31, 2019$279.73M-10.9%
FY2018Dec 31, 2018$314.06M-7.8%
FY2017Dec 31, 2017$340.68M+24.8%
FY2016Dec 31, 2016$273.06M+260.2%
FY2015Dec 31, 2015$75.82M+670.1%
FY2014Dec 31, 2014$9.85M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$437.76M-4.8%
Q1 FY2026Mar 31, 2026$375.99M-25.4%
Q4 FY2025Dec 31, 2025$449.88M-25.2%
Q3 FY2025Sep 30, 2025$511.04M-22.3%
Q2 FY2025Jun 30, 2025$459.65M-33.5%
Q1 FY2025Mar 31, 2025$503.75M-36.3%
Q4 FY2024Dec 31, 2024$601.52M-34.1%
Q3 FY2024Sep 30, 2024$658.11M-23.0%
Q2 FY2024Jun 30, 2024$691.07M-23.9%
Q1 FY2024Mar 31, 2024$791.29M-15.2%
Q4 FY2023Dec 31, 2023$912.22M-23.5%
Q3 FY2023Sep 30, 2023$854.79M+3.2%
Q2 FY2023Jun 30, 2023$908.07M+3.9%
Q1 FY2023Mar 31, 2023$933.54M+9.2%
Q4 FY2022Dec 31, 2022$1.19B+59.3%
Q3 FY2022Sep 30, 2022$828.19M+3.7%
Q2 FY2022Jun 30, 2022$874.28M+65.3%
Q1 FY2022Mar 31, 2022$855.25M+46.4%
Q4 FY2021Dec 31, 2021$748.69M+25.3%
Q3 FY2021Sep 30, 2021$798.27M+95.7%
Q2 FY2021Jun 30, 2021$529.02M+21.1%
Q1 FY2021Mar 31, 2021$584.06M+133.4%
Q4 FY2020Dec 31, 2020$597.37M+113.6%
Q3 FY2020Sep 30, 2020$407.95M+42.7%
Q2 FY2020Jun 30, 2020$436.80M+61.1%
Q1 FY2020Mar 31, 2020$250.26M+431.4%
Q4 FY2019Dec 31, 2019$279.73M-10.9%
Q3 FY2019Sep 30, 2019$285.92M-2.5%
Q2 FY2019Jun 30, 2019$271.10M-11.3%
Q1 FY2019Mar 31, 2019$47.10M-85.6%
Q4 FY2018Dec 31, 2018$314.06M-7.8%
Q3 FY2018Sep 30, 2018$293.25M+31.9%
Q2 FY2018Jun 30, 2018$305.54M+26.8%
Q1 FY2018Mar 31, 2018$327.78M+27.3%
Q4 FY2017Dec 31, 2017$340.68M+24.8%
Q3 FY2017Sep 30, 2017$222.26M-23.5%
Q2 FY2017Jun 30, 2017$241.05M–
Q1 FY2017Mar 31, 2017$257.55M–
Q4 FY2016Dec 31, 2016$273.06M–
Q3 FY2016Sep 30, 2016$290.62M–

More Intellia Therapeutics figures

See a number that looks wrong?